Similar articles

• Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data.

  Santana-Davila R, Szabo A, Arce-Lara C, Williams CD, Kelley MJ, Whittle J. Santana-Davila R, et al. J Thorac Oncol. 2014 May;9(5):702-9. doi: 10.1097/JTO.0000000000000146. J Thorac Oncol. 2014. PMID: 24662458 Free PMC article.
• Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer.

  Okamoto I, Takeda K, Daga H, Miyazaki M, Yonesaka K, Kiyota H, Tsurutani J, Ueda S, Ichikawa Y, Takeda M, Sekiguchi R, Tominaga K, Enatsu S, Nambu Y, Nakagawa K. Okamoto I, et al. Lung Cancer. 2010 Nov;70(2):168-73. doi: 10.1016/j.lungcan.2010.02.007. Epub 2010 Mar 16. Lung Cancer. 2010. PMID: 20236726
• A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer.

  Rodrigues-Pereira J, Kim JH, Magallanes M, Lee DH, Wang J, Ganju V, Martínez-Barrera L, Barraclough H, van Kooten M, Orlando M. Rodrigues-Pereira J, et al. J Thorac Oncol. 2011 Nov;6(11):1907-14. doi: 10.1097/JTO.0b013e318226b5fa. J Thorac Oncol. 2011. PMID: 22005471 Clinical Trial.
• [Lung cancer].

  Ono A, Yamamoto N. Ono A, et al. Gan To Kagaku Ryoho. 2007 Mar;34(3):367-73. Gan To Kagaku Ryoho. 2007. PMID: 17353626 Review. Japanese.
• Pemetrexed in the treatment of advanced non-small-cell lung cancer: a review of the clinical data.

  Zinner RG, Herbst RS. Zinner RG, et al. Clin Lung Cancer. 2004 Apr;5 Suppl 2:S67-74. doi: 10.3816/clc.2004.s.006. Clin Lung Cancer. 2004. PMID: 15117428 Review.